







GEMCITABINE AND OXALIPLATIN (GemOx) + RITUXIMAB

Name of the regimen and cancer drugs

Your care team may refer to your treatment as GemOx + rituximab. GemOx + rituximab consists of 3 different anti-cancer therapies.

- Gem: Gemcitabine (jem SY tuh been): Gemzar®
- Ox: Oxaliplatin (ok SA lib pla tin): Eloxatin®
- Rituximab (rih-TUK-sih-mab): Rituxan®, Ruxience®, Riabni®, Truxima®

Common uses

This regimen is mostly commonly used for Diffuse Large B-Cell Lymphoma but may be used for other cancers.

Treatment schedule

Your treatment will be given into your vein through an intravenous (IV) line. This may be into a short, flexible temporary catheter in your arm, or through a central venous catheter. A central venous catheter, or central line is a long, flexible IV tube that empties into a very large vein next to the heart. Talk with your care team to see which will be best for you and your treatment.

Each GemOx + rituximab treatment is repeated every 14 days. This is known as one cycle. Your treatment may be given for a set number of cycles, or it will keep going until the drug, or drugs, stop working or you have side effects which stop you from continuing treatment.

- ☐ Gemcitabine IV given on Day 1
- Oxaliplatin IV given on Day 1
- □ Rituximab IV or subcutaneous given on Day 1

Drug	Cycle 1	Day 1	2	3	4	5	6	7	8	 14	Cycle 2 Day 1
Gemcitabine											
Oxaliplatin											
Rituxin	nab										









GEMCITABINE AND OXALIPLATIN (GemOx) + RITUXIMAB

Other medications

Other medications may be ordered for you to prevent or treat certain side effects. These include:

	Instructions:
Growth Factors	Growth factors, like filgrastim, pegfilgrastim, and others, are medications used to treat neutropenia and prevent infections. Neutropenia is a condition where there are lower-than-normal white blood cells caused by some type of chemotherapy. Growth factors help the bone marrow to make more white blood cells.
Anti-nausea medications	You will receive medications to prevent nausea just before your chemotherapy. You may also get prescriptions for other medications to take at home, as below:
Medications to prevent allergic reactions	You will receive medications to prevent infusion related reactions prior to starting your cancer treatment.

Possible drug interactions

GemOx + rituximab may interact with other drugs you are taking. Please inform your care providers of all prescription
medicine, over-the-counter medications, vitamins, and herbal products that you take

- ☐ Talk with your care provider or pharmacist before taking new medications, supplements, or receiving any vaccines.
- ☐ Grapefruit or grapefruit juice may interact with GemOx + rituximab. Avoid eating or drinking these during your treatment.









GEMCITABINE AND OXALIPLATIN (GemOx) + RITUXIMAB

Common Side Effects

Common side effects that have been known to happen in patients receiving GemOx + rituximab are listed in the left side of this table. In some instances, the side effects may be reported less often but are still important to discuss. This table does not list all the known side effects for this therapy, only the ones that are experienced most often. Not every patient experiences every known side effect of a drug; even if you are taking the same drug as another patient, you may experience different side effects. Options to help manage any side effects that do occur are included on the right side of this table. These should be discussed with your care provider. If you experience any side effect you cannot manage or that is not listed here, contact your care provider.

Possible Side Effect	Management					
Decreased white blood cells (WBCs) and increased risk for infection	Your WBCs should be monitored by a simple blood test. When your WBCs are low, you are at a greater risk of having an in-fection. Take the following precautions to protect yourself from infection. Wash your hands often, especially before eating and after using the bathroom. Avoid crowds and people with fevers, flu, or other infection. Bathe often for good personal hygiene. Contact your care team if you experience any signs or symptoms of an infection such as: Fever (temperature more than 100.4°F or 38°C) Chills Sore throat Burning when peeing Tiredness that is worse than normal A sore that becomes red, is draining, or does not heal. Check with your care team before taking any medicine for a fever or chills.					
Decreased platelet count and increased risk of bleeding	 Your platelets should be monitored by a simple blood test. When they are low, you may bruise or bleed more easily than usual. Use caution to avoid bruises, cuts, or burns Blow your nose gently and do not pick your nose Brush your teeth gently with a soft toothbrush and maintain good oral hygiene When shaving use an electric razor instead of razor blades Use a nail file instead of a nail clipper Call your care team if you have bleeding that won't stop. Examples include: A bloody nose that bleeds for more than 5 minutes despite pressure A cut that continues to ooze despite pressure Gums that bleed a lot when you floss or brush 					
	Continued on the next page					









GEMCITABINE AND OXALIPLATIN (GemOx) + RITUXIMAB

Possible Side Effect	Management Management
Decreased platelet count and increased	Seek medical help right away if you have any severe headaches, blood in your urine or stool, coughing up blood, or bleeding that you cannot stop or lasts a long time.
risk of bleeding (continued)	You may need to take a break or "hold" your medication for medical or dental procedures. Talk to your care team or dentist before any scheduled procedures.
Decreased hemoglobin, part of the red blood cells that carry iron and oxygen	Your hemoglobin should be monitored by a simple blood test. When your hemoglobin is low, you may notice that you get tired or fatigued more easily. Try to get 7 to 8 hours of sleep per night Avoid operating heavy machinery if you feel too tired Find a balance between "work" and "rest" Stay as active as possible, but know that it is okay to rest as needed, too You might notice that you are more pale than usual Let your care team know right away if you have: Shortness of breath Dizziness Fast or abnormal heartbeat
Nausea and vomiting	 Take all medications as prescribed to help prevent and lessen symptoms of nausea and vomiting Eat and drink slowly Drink 8-10 (8-ounce) glasses of water and/or fluid (soup or broth) each day unless your care team has instructed you to limit your fluid intake Eat small, frequent meals throughout the day rather than a few large meals Eat bland foods; avoid spicy, fried, and greasy foods Avoid intense exercise immediately after eating Don't lay down right away after eating Wear loose fitting clothing for comfort Avoid strong odors. Consider getting fresh air and try deep breathing. Let your care team know if you have nausea or vomiting. Your care team may prescribe medication to help with the symptoms.
Diarrhea	 Monitor how many bowel movements you have each day. Drink 8-10 (8-ounce) glasses of water or fluid each day unless your care team has asked you to limit your fluid intake. Eat small, frequent meals throughout the day rather than a few large meals. Eat bland, low-fiber foods (such as bananas, applesauce, potatoes, chicken, rice, and toast) Avoid high fiber foods, such as raw vegetables and fruits and whole grains. Avoid foods that cause gas, such as broccoli and beans.









GEMCITABINE AND OXALIPLATIN (GemOx) + RITUXIMAB

Possible Side Effect	Management
Diarrhea (continued)	 Avoid foods with lactose, such as yogurt and milk. Avoid spicy, fried, and greasy foods Contact your care team if: The number of bowel movements you have in a day increases by 4 or more You feel dizzy or lightheaded Your care team may recommend an over-the-counter medication or prescribe something to help manage your symptoms.
Hair loss (alopecia)	 Hair will likely grow back after treatment is completed, although the color and/or texture may be different. It may take 3 to 6 months after therapy is completed to resume normal hair growth. Some people choose to wear scarves, caps, or wigs. A short haircut prior to treatment may help with stress of hair loss. Partial or complete hair loss is likely, usually 1-2 weeks after start of therapy. This hair loss can be all body hair. Be sure to keep your head covered to protect it from the sun during the summer and cold during the winter. If not covering your scalp during the summer months, be sure to use sunscreen when spending time outdoors.
Numbness or tingling in the hands or feet	Report changes in your sense of touch, such as a burning feeling, pain on the skin or weakness. Notify your care team as soon as these symptoms develop. Early intervention can limit and resolve these symptoms, but if not addressed these symptoms can become permanent.
Sensitivity to cold	Oxaliplatin can cause you to be VERY sensitive to cold for 3-7 days after treatment. • Avoid exposure to cold temperatures or touching cold objects • Avoid cold drinks, ice, and cold food. Use a straw when drinking cold liquids • Wear gloves when reaching into the freezer or handling cold objects • Wear gloves and cover your mouth with a scarf during cold weather









GEMCITABINE AND OXALIPLATIN (GemOx) + RITUXIMAB

Rare but serious side effects

	Pulmonary toxicity: Gemcitabine and oxaliplatin may result in serious and fatal lung toxicity. If you start to experience shortness of breath, fatigue, breathlessness, or discomfort/worsening of symptoms while lying on your back, immediately contact your prescriber				
	Hepatic toxicity: Gemcitabine and oxaliplatin may be harmful to your liver. Speak to your care team to know when you need to have blood tests done to monitor your liver function. If you get this side effect, your doctor may change your dose or stop treatment for some time				
	Hypersensitivity: Severe allergic reactions are a rare but serious side effect of Oxaliplatin, gemcitabine and rituximab. Seek medical attention right away if you notice difficulty breathing, swelling of the mouth or tongue, or a serious rash.				
	Intestinal obstruction/perforation: Rituximab can cause blockages to form in the large or small intestine or can cause tumors in the bowels to break down and cause perforations. Seek medical attention if you develop severe abdominal pain or other symptoms of intestinal obstruction or perforation.				
	Vesicant extravasation: Oxaliplatin has vesicant-like properties. If it leaks outside of the IV, it can cause severe damage to your skin. Notify your nurse right away if you feel any pain, aching, burning, itching, swelling, or redness at the site of your IV.				
	Live vaccinations: Talk to your care team before getting any vaccines while taking rituximab.				
	Tumor lysis syndrome. Rituximab may cause tumor lysis syndrome when starting treatment. Your care team may do blood tests to check for this side effect.				
lf y	If you experience ANY new, worsening, or uncontrolled side effects, call your care team immediately.				

(INSTITUTIONAL CONTACT INFO)









GEMCITABINE AND OXALIPLATIN (GemOx) + RITUXIMAB

Handling body fluids and waste

Some of the drugs you receive may be present in urine, stool, sweat, or vomit for many days after treatment. Many cancer drugs are toxic, your hodily waste may also be toxic and can be dangerous to come into contact with. Once you have started

	Ger	mOx + rituximab, follow the instructions below for at least two days after your treatment. This is to keep you, your loved es, and the environment as safe as possible.
		Pregnant women should avoid touching anything that may be soiled with body fluids from the patient.
		Toilet and septic systems
		• You may use the same toilet, septic tank, and/or sewer that you usually use. If you have a low-flow toilet, close the lid and flush twice to ensure that all waste has been discarded.
		If the toilet or toilet seat becomes soiled with urine, stool, or vomit, clean the surface after every use before other people use the toliet.
		Wash hands with soap and water after using the toilet for at least 20 seconds.
		If you need a bedpan, be sure your caregiver knows to wear gloves to assist with cleanup and to wash the bedpan with soap and water every day.
		If you do not have good control of bladder or bowels, use a disposable pad with a plastic back, a diaper, or a sheet to absorb body waste.
		Wash any skin that has been exposed to body waste with soap and water.
		Linens or clothing that are soiled with body fluids or body waste should be washed separately from other linens and clothing. If you do not have a washer, place the soiled linens in a plastic bag until they can be washed.
		Wash hands with soap and water after touching linens or clothing that may be soiled with body fluids.
Int	ima	acy, sexual activity, contraception, and fertility
	phy	s treatment may cause changes that can affect intimacy and sexuality, including desire and body image. Maintaining visical closeness and/or intimacy with loved ones can be continued during treatment. Holding hands, hugging, and kissing be done safely. It is recommended that you talk to your care team about any restrictions or questions you may have.
	to y trea + ri	me treatments can influence the ability to have children, also known as fertility. If you're interested in preserving fertility, tally our care team before treatment. Ask your healthcare provider to determine when it is safe to become pregnant after your atment. Patients of reproductive ability should not become pregnant or get their partners pregnant while receiving GemOx tuximab. Some of the drugs you receive may be present in semen and vaginal secretion for many days after treatment. You had use barrier devices, such as condoms, during sexual activity to limit exposure to body fluids.
	С	alk to your care team about birth control. Not all options may be right for your treatment or cancer. Effective contraception ould include one or more of the following: barrier methods (e.g. condoms), hormone methods (e.g. birth control pills), or urgery.
	J T	ell your care team if you become pregnant or plan to breastfeed.









GEMCITABINE AND OXALIPLATIN (GemOx) + RITUXIMAB

Additional resources

Prescribing information:

Gemcitabine: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020509s033lbl.pdf **Oxaliplatin:** https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021492s016lbl.pdf

Rituximab: https://www.gene.com/download/pdf/rituxan_prescribing.pdf

Additional instructions

Updated – July 31, 2022

Important notice: The Association of Community Cancer Centers (ACCC), Hematology/Oncology Pharmacy Association (HOPA), National Community Oncology Dispensing Association, Inc. (NCODA), and Oncology Nursing Society (ONS) have collaborated in gathering information for and developing this patient education guide. This guide represents a brief summary of the therapy derived from information provided by the drug manufacturer and other resources. This guide does not cover all existing information related to the possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with this therapy and should not substitute for the advice of a qualified healthcare professional. Provision of this guide is for informational purposes only and does not constitute or imply endorsement, recommendation, or favoring of this therapy by ACCC, HOPA, NCODA, or ONS, who assume no liability for and cannot ensure the accuracy of the information presented. The collaborators are not making any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual receiving therapy. All decisions related to receiving this therapy should be made with the guidance and under the direction of a qualified healthcare professional.

Permission: Intravenous Cancer Treatment Education (IVE) sheets are provided as a free educational resource for patients with cancer in need of concise, easy-to-understand information about intravenous cancer therapy. Healthcare providers are permitted to copy and distribute the sheets to patients as well as direct patients to the OCE website for information. However, commercial reproduction or reuse, as well as rebranding or reposting of any type, are strictly prohibited without permission of the copyright holder. Please email permission requests and licensing inquiries to Contact@NCODA.org.

Copyright © 2021 by NCODA. All rights reserved.